Status:
COMPLETED
Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder
Lead Sponsor:
Eli Lilly and Company
Conditions:
Attention Deficit Disorder With Hyperactivity
Eligibility:
All Genders
6-16 years
Phase:
PHASE3
Brief Summary
The study is designed to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy (in the morning). It incorporates a 6-week acute treatment pe...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Subjects must have ADHD that meets the DSM-IV criteria
- Aged 6 to 16 years.
- Subjects must not have taken any medication used to treat ADHD.
- Laboratory results must show no significant abnormalities
- Baseline ECG results must not show an abnormality
- Subjects must be able to swallow capsules.
- Subjects must be of normal intelligence.
- Exclusion Criteria
- Weigh less than 20 kg or more than 60 kg at study entry.
- Subjects who, after an adequate trial with methylphenidate or amphetamine experience some benefit in ADHD signs and symptoms are excluded from participating.
- Have a history of Bipolar I or II disorder, psychosis, or PDD.
- Meet DSM-IV criteria for an anxiety disorder.
- Have a history of any seizure disorder.
- Patients at serious suicidal risk.
- Patients with narrow angle glaucoma
- Subjects who have a history of severe allergies .
- Have a history of alcohol or drug abuse within the past 3 months
- Screen positive for drugs of abuse not prescribed by a physician.
- Have cardiovascular disease and an increased heart rate and blood pressure.
- Have a medical condition that would increase sympathetic nervous system activity markedly or who are taking a medication on a daily basis.
- Have severe gastrointestinal narrowing
- Are during the study time likely to need psychotropic medications.
- Are likely to begin a structured psychotherapy aimed at ADHD symptoms.
- Have used a monoamine oxidase inhibitor (MAOI) during the 2 weeks
- Female subjects who are pregnant or who are breast-feeding.
- Are investigative site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study.
- Are, in the opinion of the investigator, unsuitable in any other way to participate in this study.
- Are employed by Lilly.
Exclusion
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2005
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT00386581
Start Date
July 1 2004
End Date
February 1 2005
Last Update
June 12 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Moscow, Russia